Announcement of Receiving ISO13485 Certification

This material is an English translation of the press release issued on November 25, 2024 in Japanese, and the Japanese release is given priority regarding content and interpretation.

November 25, 2024

Mochida Pharmaceutical Co., Ltd.

Mochida Pharmaceutical Co., Ltd. (Head office: Shinjuku-ku, Tokyo, President: Naoyuki Mochida, hereinafter called “Mochida”) announces that Mochida has received ISO 13485 certification, the international standard for quality management system for medical devices.

The scope of this certification is “Design, development and manufacture of sterile reparative medical products for injury site using alginic acid”. Receiving ISO 13485 certification indicates that Mochida’s quality management system for alginate-based medical devices that we design, develop and manufacture meets the applicable requirements.

In order to achieve the “Vision for 2031”, announced two years ago, Mochida Pharmaceutical Group is working to position the biomaterials business as one of the pillars of the next generation in addition to the current mainstay pharmaceutical and healthcare businesses. The biomaterials business is advancing the development of medical devices based on alginate, which is expected to have various medical applications, and will expand globally. Following this certification, we will continue to strive to develop high quality medical devices and contribute to the field of medical care.

Summary of the certification

Certification Standard	:	ISO13485:2016
Organization	:	Mochida Pharmaceutical Co., Ltd.
Registration Date	:	2024-11-07
Certificate No	:	MD782202
Location	:	1. Head Office 1-7 Yotsuya, Shinjuku-ku, Tokyo 160-8515 Japan 2. Fujieda site 342 Gensuke, Fujieda, Shizuoka 426-8640 Japan
Registered Activities	:	1. Design, development and manufacture of sterile reparative medical products for injury site using alginic acid 2. Design, development of sterile reparative medical products for injury site using alginic acid